Table 3.
Representative BTZ-based nanoformulations in cancer therapy.
| Drug Delivery Systems | Nanocarriers | Drug | Ligand/Target | Cancers | Ref. |
|---|---|---|---|---|---|
| Liposomes | DODEAC, DEX, cholesterol | BTZ, DEX | DEX/GR | WM | [114] |
| Liposomes | PSGL-1, DPPC, Cholesterol | BTZ, Y27632 | PSGL-1/P-selectin | MM | [115] |
| Liposomes | HSPC, Cholesterol, DSPE-PE2000-MAL | BTZ | NGR/aminopeptidase N | Neuroblastoma | [26] |
| Polymeric micelles | catechol-functionalized PC, PEG | BTZ | / | Breast cancer | [116] |
| Polymeric micelles | PEG-b-PCL | BTZ | / | Hepatocellular carcinoma | [117] |
| Polymeric micelles | HA-P(TMC-co-DTC) | BTZ | HA/CD44 | Multiple myeloma | [118] |
| Polymeric micelles | DSPE-PEG, polydopamine | BTZ, DOX | / | Breast cancer | [119] |
| Dendrimers | PEG-PAMAM-Cat | BTZ | cRGD/Integrin αvβ3 | Breast cancer | [120] |
| Dendrimers | G5-PAMAM-KAC-Cat | BTZ | / | Breast cancer | [121] |
| Nanogels | HA, acylate anhydride, dopamine | BTZ | HA/CD44 | Hepatocellular carcinoma | [122] |
| Nanogels | pNIPAAm-co-pAAm | BTZ | / | Colon cancer | [123] |
| Nanogels | PLL−P(LP-co-LC), mPEG-b-PLL/DMMA | BTZ, CA4P | / | Colon cancer | [124] |
| Nanogels | P(Gu)5-PEG-P(Gu)5, P(Bor)5-PEG-(Bor)5, | BTZ | / | Multiple myeloma | [125] |
| Inorganic nanoparticles | MSNs | BTZ | HP/MMP2/9 | Lung cancer | [126] |
| Inorganic nanoparticles | chitosan, magnetic iron oxide | BTZ | / | Breast cancer | [127] |
| Inorganic nanoparticles | mSiO2-H2A | BTZ | / | Cervical cancer | [128] |
| Inorganic nanoparticles | p(HEMA-co-DMA), superparamagnetic iron oxide | BTZ | / | Squamous-cell carcinoma | [129] |
| Biomimetic nanoparticles | macrophage membrane | BTZ | T7/TFR | Breast cancer | [130] |
| Biomimetic nanoparticles | phage P22 virus capsids | BTZ | / | Hepatocellular carcinoma | [131] |